IL138307A0 - PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL]-4-PIPERIDINEMETHANOL - Google Patents

PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL]-4-PIPERIDINEMETHANOL

Info

Publication number
IL138307A0
IL138307A0 IL13830799A IL13830799A IL138307A0 IL 138307 A0 IL138307 A0 IL 138307A0 IL 13830799 A IL13830799 A IL 13830799A IL 13830799 A IL13830799 A IL 13830799A IL 138307 A0 IL138307 A0 IL 138307A0
Authority
IL
Israel
Prior art keywords
piperidinemethanol
dimethoxyphenyl
fluorophenyl
ethyl
processes
Prior art date
Application number
IL13830799A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc, Hoechst Marion Roussel De Gmbh filed Critical Aventis Pharma Inc
Publication of IL138307A0 publication Critical patent/IL138307A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13830799A 1998-03-13 1999-03-11 PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL]-4-PIPERIDINEMETHANOL IL138307A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4225198A 1998-03-13 1998-03-13
US25071899A 1999-02-16 1999-02-16
PCT/US1999/005332 WO1999046245A2 (en) 1998-03-13 1999-03-11 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL

Publications (1)

Publication Number Publication Date
IL138307A0 true IL138307A0 (en) 2001-10-31

Family

ID=26719032

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13830799A IL138307A0 (en) 1998-03-13 1999-03-11 PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL]-4-PIPERIDINEMETHANOL
IL138307A IL138307A (en) 1998-03-13 2000-09-06 Processes and intermediates for the preparation of (R) -α– (2,3, dimethoxynil) - 1- [2- (4-fluorophenyl) ethyl] - 4-piperidinemethanol
IL175983A IL175983A0 (en) 1998-03-13 2006-05-29 Processes and intermediates for the preparation of (r) -??-(2,3 - dimethoxyphenyl) - 1 - [2 - (4-fluorophenyl) ethyl] - 4 - piperidine methanol

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL138307A IL138307A (en) 1998-03-13 2000-09-06 Processes and intermediates for the preparation of (R) -α– (2,3, dimethoxynil) - 1- [2- (4-fluorophenyl) ethyl] - 4-piperidinemethanol
IL175983A IL175983A0 (en) 1998-03-13 2006-05-29 Processes and intermediates for the preparation of (r) -??-(2,3 - dimethoxyphenyl) - 1 - [2 - (4-fluorophenyl) ethyl] - 4 - piperidine methanol

Country Status (25)

Country Link
EP (3) EP1734037A3 (ko)
JP (2) JP4511723B2 (ko)
KR (7) KR100591643B1 (ko)
CN (1) CN100436415C (ko)
AR (1) AR015540A1 (ko)
AT (1) ATE373639T1 (ko)
AU (1) AU755436B2 (ko)
BR (1) BR9909260A (ko)
CA (1) CA2322501C (ko)
CY (1) CY1107104T1 (ko)
DE (1) DE69937162T2 (ko)
DK (1) DK1192134T3 (ko)
DZ (1) DZ2742A1 (ko)
EG (1) EG24052A (ko)
ES (1) ES2294838T3 (ko)
HK (1) HK1042484B (ko)
HU (1) HUP0400889A3 (ko)
IL (3) IL138307A0 (ko)
MA (1) MA25515A1 (ko)
NO (1) NO317981B1 (ko)
NZ (1) NZ506807A (ko)
PT (1) PT1192134E (ko)
TN (1) TNSN99035A1 (ko)
TW (1) TWI249526B (ko)
WO (1) WO1999046245A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
EP1370244A1 (en) * 2001-03-12 2003-12-17 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
US8964338B2 (en) 2012-01-11 2015-02-24 Emerson Climate Technologies, Inc. System and method for compressor motor protection
EP2971989A4 (en) 2013-03-15 2016-11-30 Emerson Electric Co REMOTE MONITORING AND DIAGNOSIS FOR A HVAC SYSTEM
CN112358398A (zh) * 2020-11-19 2021-02-12 山东新华制药股份有限公司 D-(+)-二对甲苯甲酰酒石酸的回收制备方法
CN116082705B (zh) * 2022-12-05 2023-09-12 苏州易昇光学材料股份有限公司 一种抗黄变自修复凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260623A (en) * 1979-11-26 1981-04-07 Warner-Lambert Company Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
WO1991018602A1 (en) * 1990-06-01 1991-12-12 Merrell Dow Pharmaceuticals Inc. (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
AU650031B2 (en) * 1990-06-07 1994-06-09 Aventisub Ii Inc. 1-Piperidinyl alkanoylarylsulfonamide derivatives
US5477029A (en) * 1994-01-28 1995-12-19 Skutt Ceramic Products, Inc. Kiln with hinged control panel
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
KR20060002035A (ko) 2006-01-06
JP4511723B2 (ja) 2010-07-28
KR20060002034A (ko) 2006-01-06
CA2322501C (en) 2006-05-09
DK1192134T3 (da) 2007-11-26
KR20060002038A (ko) 2006-01-06
KR100591642B1 (ko) 2006-06-20
MA25515A1 (fr) 2002-10-01
TWI249526B (en) 2006-02-21
DZ2742A1 (fr) 2003-09-08
AR015540A1 (es) 2001-05-02
KR100586327B1 (ko) 2006-06-08
EP1192134B1 (en) 2007-09-19
KR20060002036A (ko) 2006-01-06
NZ506807A (en) 2003-03-28
HUP0400889A2 (hu) 2004-08-30
CN100436415C (zh) 2008-11-26
DE69937162T2 (de) 2008-06-12
AU755436B2 (en) 2002-12-12
DE69937162D1 (de) 2007-10-31
NO20004545L (no) 2000-11-13
AU2998899A (en) 1999-09-27
WO1999046245A3 (en) 1999-10-21
IL175983A0 (en) 2006-10-05
KR100591640B1 (ko) 2006-06-20
KR100591997B1 (ko) 2006-06-26
EG24052A (en) 2008-04-13
HUP0400889A3 (en) 2010-08-30
JP2010143925A (ja) 2010-07-01
KR20060002037A (ko) 2006-01-06
EP1736469A3 (en) 2010-06-09
HK1042484B (zh) 2008-05-02
CN1300280A (zh) 2001-06-20
EP1734037A2 (en) 2006-12-20
KR100586328B1 (ko) 2006-06-08
WO1999046245A2 (en) 1999-09-16
KR100591641B1 (ko) 2006-06-20
BR9909260A (pt) 2000-11-21
CA2322501A1 (en) 1999-09-16
KR20060002039A (ko) 2006-01-06
ATE373639T1 (de) 2007-10-15
IL138307A (en) 2006-09-05
KR100591643B1 (ko) 2006-06-20
NO20004545D0 (no) 2000-09-12
JP2002506059A (ja) 2002-02-26
ES2294838T3 (es) 2008-04-01
HK1042484A1 (en) 2002-08-16
KR20010041819A (ko) 2001-05-25
EP1736469A2 (en) 2006-12-27
EP1734037A3 (en) 2010-06-16
EP1192134A2 (en) 2002-04-03
TNSN99035A1 (fr) 2005-11-10
PT1192134E (pt) 2007-11-13
CY1107104T1 (el) 2012-01-25
NO317981B1 (no) 2005-01-17

Similar Documents

Publication Publication Date Title
IL175983A0 (en) Processes and intermediates for the preparation of (r) -??-(2,3 - dimethoxyphenyl) - 1 - [2 - (4-fluorophenyl) ethyl] - 4 - piperidine methanol
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU1987400A (en) Process for preparation of paroxetine maleate
PL344994A1 (en) Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems
GB2344586B (en) Isoquinuclidine derivatives,method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds
HUP9701364A3 (en) Procedure for making (r) and (s) isomers of alfa-metil-2-[3-(trifluor-metil)-fenil]-etil-amin and the isomers and salts
AU1037901A (en) Process for the preparation of paroxetine
AU3818900A (en) Process for the preparation of substituted piperidines
AU5553200A (en) Process for the preparation of paroxetine and structurally related compounds
AU6870600A (en) Process for the preparation of 2,3-dihydroazepine compounds
HUP0004503A3 (en) Process for the preparation of paroxetine hydrochloride
ZA991907B (en) Novel processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
HUP9900761A3 (en) A process for the preparation of 4-(desdimethyl-amino)-tetracyclines
AU6481799A (en) Process for the preparation of paroxetine hydrochloride
AU1396400A (en) Process for the preparation of paroxetine hydrochloride
AU6010099A (en) Process for the preparation of an n-alkyl or n-aryl carbamoyl derivative
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL142479A0 (en) Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907
AU5982199A (en) Process for the preparation of 4,4'-dihalogen-o-hydroxydiphenyl compounds
AU5779998A (en) Process for the preparation of cyanoarylmethylamine
ZA989842B (en) Esters of (+)-Ó-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol.
AU6875800A (en) Heterocyclic compounds and process for the preparation thereof
SI1192134T1 (sl) Postopki za pripravo (R)-alfa-(2,3-dimetoksifenil)-1-2-(4-fluorofenil) etil)-4-piperidinmetanola
AU1396600A (en) Process for the preparation of paroxetine hydrochloride

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed